Pacific Edge Maintains Steady Test Volumes

Pacific Edge Limited (PFGTF) has released an update.

Pacific Edge Limited reports a steady number of Cxbladder diagnostic tests in Q1 2025, with a slight 0.3% decrease from the previous quarter, despite a reduced US sales team and ongoing Medicare reimbursement challenges. The company saw a notable increase in test volumes from the Asia Pacific region, particularly New Zealand, and continued growth through Kaiser Permanente’s increased usage of Cxbladder. These developments indicate improved sales force efficiency and a growing acceptance of Cxbladder’s clinical value in bladder cancer diagnostics.

For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.